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A B S T R A C T
Purpose
With three available chemotherapy drugs for advanced colorectal cancer (CRC), response rate (RR)
and survival outcomes have improved with associated morbidity, accentuating the need for tools
to select optimal individualized treatment. Pharmacogenetics identifies the likelihood of adverse
events or response based on variants in genes involved in drug transport, metabolism, and
cellular targets.
Patients and Methods
Germline DNA was extracted from 520 patients on the North American Gastrointestinal Intergroup
N9741 study. Three study arms were evaluated: IFL (fluorouracil [FU]  irinotecan [IRN]), FOLFOX
(FU  oxaliplatin), and IROX (IRN  oxaliplatin). Information on adverse events, response, and
disease-free survival was available. Thirty-four variants in 15 candidate genes for analysis based on
previous associations with adverse events or outcome were assessed. Genotyping was per-
formed using pyrosequencing.
Results
All variants were polymorphic. The homozygous UGT1A1*28 allele observed in 9% of patients
was associated with risk of grade 4 neutropenia in patients on IROX (55% v 15%; P  .002).
Deletion in GSTM1 was associated with grade 4 neutropenia after FOLFOX (28% v 16%; P  .02).
Patients with a homozygous variant genotype for GSTP1 were more likely to discontinue FOLFOX
because of neurotoxicity (24% v 10%; P  .01). The presence of a CYP3A5 variant was
significantly associated with RR on IFL (29% v 60%; P  .0074). Most previously published
genotype-toxicity or -efficacy relationships were not validated in this study.
Conclusion
This study provides a platform to evaluate pharmacogenetic predictors of response or severe
adverse events in advanced CRC. Pharmacogenetic studies can be conducted in multicenter trials,
and our findings demonstrate that with continued research, clinical application is practical.
J Clin Oncol 28:3227-3233. © 2010 by American Society of Clinical Oncology
INTRODUCTION
The practice of medicine is in the midst of a transi-
tion from the current reliance on treatment based on
average outcomes across populations to biologically
based patient management. A number of factors
drive these efforts, including the challenge of select-
ing among equivalent therapies, the emerging influ-
ence of the patient in health care decisions, and the
realization that health care systems cannot afford
ineffective, yet expensive, medications. The applica-
tion of pharmacogenetic techniques provides an op-
portunity to enrich the proportional benefit to
patients in an economical manner. This is especially
true in cancer therapy, where initial treatment pro-
vides the best opportunity for disease control or
palliation. In addition, the adverse drug events from
chemotherapy can be severe, debilitating (even le-
thal), and expensive, making therapies associated
with equal efficacy and less adverse events attractive
to patients and practitioners alike.1,2
Recent clinical studies suggest that genomic
findings can translate into improvements in clinical
practice.3-8 Indeed, many studies have suggested an
association between genetic variants and either ad-
verse events or efficacy end points. However, these
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studies are often small ( 100 patients), from a single center, and do
not have comparative treatment arms in which to determine whether
a marker is prognostic only for overall outcome or allows prediction
for an effect of a specific therapy.
Colorectal cancer (CRC) is a disease for which the management
could be optimized using pharmacogenetics. The treatment has
changed because of the availability of three cytotoxic drugs with
distinct mechanisms of action, in addition to antibody therapy
(bevacizumab, cetuximab, and panitumumab).9-13 These drugs have
improved the tumor response, progression-free survival (PFS), and
overall survival (OS) of some patients with CRC, but are associated
with important drug-specific adverse events. In addition, the cost of
these treatments is  $100,000 per year for many patients.1 The
development of multiple active regimens for treatment of this disease
is encouraging but, to date, there have been no prospective tools
validated that permit selection of the best therapy for an individual
patient. The North American Gastrointestinal Intergroup N9741
study (hereafter N9741) of chemotherapy for metastatic CRC offered
a unique opportunity for pharmacogenetic research.14 This trial pro-
spectively included pharmacogenetic sampling in the context of a
multicenter study of patients randomly assigned to the three main
cytotoxic agents for treating advanced CRC (fluorouracil [FU], irino-
tecan [IRN], and oxaliplatin). The goal of this work was to assess the
impact of published candidate genetic markers for which studies had
identified a putative role in the prediction of adverse events or activity
in patients receiving combination chemotherapy for advanced CRC.
PATIENTS AND METHODS
Patient Population
The N9741 clinical study has been previously detailed.14 Patients char-
acteristics are presented in Table 1. Three regimens—IFL, FOLFOX, and
IROX—were tested in this study. Initially, IFL was IRN at 125 mg/m2 and
bolus FU at 500 mg/m2 plus leucovorin at 20 mg/m2 on days 1, 8, 15, and 22
every 6 weeks. Midway through the trial, due to adverse events considerations,
the doses of IRN and FU were reduced to 100 mg/m2 and 400 mg/m2, respec-
tively.15 FOLFOX was oxaliplatin at 85 mg/m2 on day 1 and bolus FU at 400
mg/m2 plus leucovorin at 200 mg/m2 followed by FU at 600 mg/m2 in 22-hour
infusions on days 1 and 2 every 2 weeks. IROX was oxaliplatin at 85 mg/m2 and
IRN at 200 mg/m2 every 3 weeks. Treatment continued until progression,
unmanageable toxic adverse effects, or withdrawal of consent.
Toxic adverse effects (except paresthesia) were graded using National
Cancer Institute Common Terminology Criteria for Adverse Events version
2.0. Paresthesias that resulted in functional impairment that interfered with
daily activities or caused disability were classified as grade 3 or 4, respectively.
Any grade 3 or 4 toxic effect resulted in an approximately 20% dose reduction
for subsequent cycles. The specific adverse events tested for association with
genetic markers were diarrhea, vomiting, paresthesia, febrile neutropenia (all
grade  3), and neutropenia (grade  4). Response was evaluated by com-
puted tomography before therapy and every 6 weeks during therapy until an
objective response was attained (either complete or partial response) or the
patient progressed. Confirmed response was defined as an objective status of
complete or partial response maintained for at least 4 weeks.
Genetic Analysis
A 20-mL blood sample was obtained in EDTA lavender-top tubes from
each patient after written informed consent. The addition of blood sampling
for pharmacogenetic studies was approved by each local institutional review
board. Blood was obtained at study registration. Each blood tube was labeled
with a unique identifier and contained no clinical or demographic informa-
tion. Genomic DNA was extracted from EDTA tubes using standard tech-
niques and stored at 4°C before use. Genetic variants in FU, oxaliplatin, or
IRN drug pathways were selected for analysis, primarily on the basis of
association (in previous literature) with adverse events or outcome with one
or more of the study drugs (Table 2).5,16 Five genes were prespecified in the
clinical protocol as of primary interest: TYMS, DPYD, CYP3A4, UGT1A1, and
GSTM1. A total of 34 variants (30 single nucleotide polymorphisms [SNPs],
one insertion/deletion, two tandem repeats, and one gene deletion) were
assessed using polymerase chain reaction and pyrosequencing technologies as
previously described (assay information is available in the Data Supplement,
online only).17
Statistical Analysis
The primary analyses were specified to compare adverse events and
activity measures overall and by treatment arm for each polymorphism. Every
variant was evaluated for association with every end point. The total number of
statistical tests performed was not quantified, and formal protection for mul-
tiple comparisons was not attempted. However, as a general protection against
multiple comparisons, since five genes were selected to be of primary interest,
a two-sided significance level of 0.01 (as opposed to the usual 0.05) was used to
Table 1. Descriptive Baseline Information on the Initial 520 Patients With
Blood Sampling for Pharmocogenetics Study and 1,174 Patients for







PNo. % No. %
Age, years




Measurable 983 84 453 87
Evaluable 189 16 67 13
ECOG PS .81
0-1 1,115 95 496 95
2 57 5 24 5
Sex .28
Female 450 38 214 41
Male 724 62 306 59
Prior adjuvant chemotherapy .86
Yes 171 15 78 15
No 1,001 85 442 85
Race/ethnicity .21
White 1,013 86 450 87
Black 92 8 36 7
Hispanic 42 4 16 3
Other 16 14 9 2
Asian 11 1 9 2
Grade  3 adverse events
Nausea 147 13 62 12 .69
Dehydration 60 5 31 6 .49
Grade  4 neutropenia 190 16 93 18 .42
Vomiting 131 11 54 10 .61
Diarrhea 254 22 93 18 .07
Febrile neutropenia 103 9 42 8 .61
Paresthesia 92 8 44 8 .69
Median time to event
outcomes (months)
Time to progression 7.5 8.2 .04
Overall survival 17.0 18.1 .15
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, perfor-
mance status.
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declare statistical significance for any finding; P values from .01 to .05 were
considered promising. Given the multitude of statistical tests performed, no
positive association should be considered definitive. There were at least 1,088
tests (34 variants  eight outcomes [five toxicity, three efficacy]  four
populations [overall, IFL, FOLFOX, IROX]) excluding interaction testing.
Correlation of dichotomous outcomes and genotype status were tested
using 2 tests; odds ratios and associated 95% CIs were reported as estimates of
the association. Univariate logistic regression models were used to explore the
association between continuous variables and binary outcomes; multivariate
logistic regression was used to adjust for known risk factors (performance
status, sex, age). Cox proportional hazards models were used to assess the
relationship between polymorphisms and the time to event outcomes, time to
progression, and OS. UGT1A1*28 was tested as a three-level variable (6/6, 6/7,
and 7/7 genotypes) using a Cochran-Armitage test for trend for association
with categorized outcomes (toxicity and tumor response). Because paresthe-
sias associated with oxaliplatin-based therapy are cumulative and dose-
dependent, we also performed analyses for the association between genetic
variants and time to the development of neurotoxicity.
RESULTS
Written informed consent for pharmacogenetic studies was ob-
tained from 547 (49%) of the 1,118 patients accrued to N9741 from
the time of the amendment to include blood sampling. Usable
specimens were obtained from 520 (95%) of the 547 patients: 114
on IFL, 299 on FOLFOX4, and 107 on IROX. A total of 92 (81%) of
the 114 patients treated with IFL received the reduced IFL doses, in
which IRN was reduced from 125 to 100 mg/m2/dose and FU was
reduced from 500 to 400 mg/m2/dose. However, because of
protocol-specified toxicity-based dose reductions before the pro-
tocol amendment, the two IFL cohorts received similar total cu-
mulative doses of IRN. Table 1 compares demographics for
patients participating or not in the pharmacogenetic studies. No
differences are present in the demographic features, incidence of
Table 2. Genotype and Allele Frequencies for the North American Gastrointestinal Intergroup Trial N9741 Patients for Toxicity and Outcome Polymorphisms
Gene Nucleotide Amino Acid n
Genotype Frequency Allele Frequency
wt/wt wt/var var/var p q
ABCB1 1236 CT G411G 526 168 257 101 0.56 0.44
ABCB1 3435 CT I1145I 540 157 275 108 0.55 0.45
ABCB1 2677 GT A893S 541 162 253 103 0.55 0.43†
ABCC1 IVS18-30 CG Intron 18 540 369 157 14 0.83 0.17
ABCC1 4002 GA S1334S 547 300 210 37 0.74 0.26
ABCC2 24 CT 5UTR 543 363 157 23 0.81 0.19
ABCC2 4544 GA C1515Y 545 486 57 2 0.94 0.06
ABCC2 1058 GA R353H 548 546 2 0 0.999 0.001
ABCC2 1249 GA V417I 542 336 170 36 0.78 0.22
ABCC2 3972 GA I1324I 492 198 247 47 0.65 0.35
ABCG2 421 CA Q141K 507 401 101 5 0.89 0.11
CYP3A4 329 AG (1B) Promoter 540 473 49 18 0.92 0.08
CYP3A4 1334 TC (3) M445T 516 510 6 0 0.99 0.01
CYP3A5 6986 AG (3C) Splice variant 76 449 547 22 0.11 0.89
CYP3A5 14690 GA (6) Splice variant 545 533 12 0 0.99 0.01
DPYD IVS14  1 GA (2A) Intron 4 544 540 4 0 0.996 0.004
DPYD 1627 AG (5) I543V 520 342 155 23 0.81 0.19
DPYD 2194 GA (6) V732I 546 498 45 3 0.95 0.05
DPYD 85 TC (9A) C29R 546 319 192 35 0.76 0.24
ERCC1 354 CT N118N 521 188 238 95 0.59 0.41
ERCC2 1989 AG Promoter 402 148 164 90 0.57 0.43
ERCC2 2133 CT D711D 512 256 188 68 0.68 0.32
ERCC2 2251 AG K751Q 547 236 235 76 0.65 0.35
GSTM1 0 Null 548 N/A N/A N/A 53% 47%‡
GSTP1 2293 CT A114V 547 474 73 0 0.93 0.07
GSTP1 1578 AG I105V 463 194 220 49 0.66 0.34
MTHFR 677 CT A222V 541 263 225 53 0.69 0.31
MTHFR 1298 AC E429A 537 258 223 56 0.69 0.31
MTHFR 1793 GA R549Q 545 490 51 4 0.95 0.05
TYMS 1494del 3UTR 546 257 223 66 0.67 0.33
TYMS TSER Enhancer 321 103 132 86 0.53 0.47§
UGT1A1 3156 GA (93) Enhancer 520 262 217 41 0.71 0.29
UGT1A1 (TA)nTAA (28) Promoter 468 224 206 32 0.703 0.291¶
XRCC1 1196 GA R399Q 534 231 239 64 0.66 0.34
Abbreviations: wt, wild type; var, variant; p, wild-type allele frequency; q, variant allele frequency.
†ABCB1 2677 is a tri-allelic (2677 GT/A) variant with an A allele (threonine allele) frequency of 2%.
‡GSTM1 0 is a deletion polymorphism. Results are stated as percentage of patients with at least one copy of the gene (wt) versus patients with a homozygous
gene deletion (var).
§TYMS TSER is a tandem repeat polymorphism. Results are stated as three copies of the repeat (wt) or two copies of the repeat (var).
¶UGT1A1 (TA)nTAA is a repeat polymorphism. Results are stated as six copies of the repeat (wt) or seven copies (var). Alleles containing five or eight copies of
the repeat were found at a combined allele frequency of 0.6%.
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severe systemic toxicity, PFS, or OS of patients with and without
blood samples (Table 1, Fig 1).
A total of 34 variants in 15 genes were assessed (18,598 geno-
types). All variants were polymorphic in the patient population. All
variants were in Hardy-Weinberg equilibrium after correction for
ethnicity. The observed allele frequency of all variants was consistent
with that in previously published literature. The frequency of a ho-
mozygous rare variant genotype ranged from less than 0.1%
(DPYD*2A) to 47% (GSTM1 deletion; Table 2). Of note, a DPYD*2A
heterozygous genotype occurred in 0.74% of patients. Statistically
significant ethnic differences between whites and African Americans
were present for 10 (29%) of 34 variants.
Adverse Events
A complete set of associations between each SNP and each ad-
verse event considered, overall and by treatment arm, is included in
the Data Supplement. UGT1A1*28 (P  .003) and UGT1A1 3156
CT (P  .001) were associated with an increased rate of grade  4
neutropenia, and UGT1A1 3156 CT with an increased rate of
grade 3 febrile neutropenia (P  .005), pooling across all study arms.
Further associations with adverse events were specific to each treat-
ment arm on the study.
Neutropenia. The presence of the homozygous UGT1A1*28
allele (seven T/A repeats) was observed in 9% of patients and was
associated with the risk of grade 4 neutropenia (Fig 2A). In patients
receiving the IFL regimen, the impact of UGT1A1*28 was modest,
with a risk of 18% grade 4 neutropenia in the homozygous patients
(P .25). The effect was more dramatic in patients receiving the IROX
regimen, where 55% of homozygous patients experienced grade 4
neutropenia compared with 10% in six of six patients and 15% in six
of seven patients (P  .002). UGT1A1*28 homozygous patients on the
FOLFOX regimen also had a trend toward an elevation in grade 4
neutropenia risk (P  .11). The UGT1A1 3156 GA putative 5
promoter enhancer module SNP (UGT1A1*93) also displayed similar
predictive results, consistent with the high degree of linkage between
this variant and UGT1A1*28.
GSTM1*0 was observed in 47% of patients (Table 2). Differential
associations with grade 4 neutropenia were seen across the treatment
arms. Severe neutropenia in patients on the IFL and IROX arms did
not appear to be different based on GSTM1*0 genotype, whereas
FOLFOX-treated patients with GSTM1*0 had a 1.7-fold higher risk
compared with patients with an intact gene (28% v 16%; P  .016; Fig
3). The GSTP1 status (variants at either codon 105 or 114) was related
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Fig 1. Graphical demonstration that overall survival was not different between
patients with blood samples for pharmacogenetic study and patients without
blood sampling. Blue line, patients who had no blood drawn; gold line, patients
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Fig 2. UGT1A1*28 genotype and severe neutropenia (A) or confirmed response
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Fig 3. Relationship between GSTM1*0 and grade 4 neutropenia. IFL, fluorou-
racil (FU)  irinotecan (IRN); FOLFOX, FU  oxaliplatin; IROX, IRN  oxaliplatin.
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FOLFOX, with a rate of 14% in patients with the T/T genotype com-
pared to 3% in the other patients (P  .001).
Neurotoxicity. Severe paresthesias were therapy-limiting ad-
verse events in patients receiving oxaliplatin on either the FOLFOX or
IROX arms. Indeed, 61% of patients in this cohort came off therapy
for reasons other than progressive disease on the FOLFOX arm.18
Thus, we tested the hypothesis that genetic variation in either excision
repair or detoxification of platinum adducts would be associated with
risk of oxaliplatin-related peripheral neuropathy. Genetic variants in
GSTM1, XRCC1, ERCC1, and ERCC2 were not associated with neu-
rotoxicity. Patients with a GSTP1 I105V genotype of T/T were more
likely to discontinue FOLFOX because of neurotoxicity (24% v 10%
for other; P  .01). In addition, in patients treated with IROX, only
patients with T/T genotype experienced grade 3 neurotoxicity (eight
of 43, 18.6% v none of 54, 0%; P  .003). This trend, however, was not
present in FOLFOX-treated patients, where the rate of grade  3
neurotoxicity was similar in T/T and other patients (11.7% and 11.9%
respectively; P  .70).
Vomiting. In patients treated with IROX, UGT1A1 3156 CT
was associated with the rate of grade 3 vomiting, with rates of 71.4% in
UGT1A1*93 (A/A) patients, as opposed to 22.1% in the comparative
group (P  .004).
Efficacy
A complete set of associations between each SNP and the efficacy
outcomes of response rate (RR), time to progression, and OS, overall
and by treatment arm, is included in the Data Supplement. Pooling all
arms, only TYMS 1494del had univariate prognostic significance for
confirmed tumor response (RR, 51.7% for A/A patients, 39.2% for
other; P  .0051). This was present in all arms with virtually identical
magnitude (IFL, 41% v 29%; FOLFOX, 58% v 46%; and IROX, 45% v
33%). Within treatment arms, the presence of CYP3A5*3C was signif-
icantly associated with confirmed response on IFL (RR, 29% v 60%;
P  .0074; Fig 4). No SNPs were significant predictors of PFS or OS,
overall or in the three treatment arms individually.
The presence of a UGT1A1*28 allele did not impact the con-
firmed RR in the IFL or FOLFOX arms (P  .75 and P  .76,
respectively; Fig 2B). UGT1A1*28/*28 patients on the IROX arm had
a trend toward a decreased RR (P  .02). Neither the TYMS enhancer
region 28 base pair tandem repeat (TSER) nor the 3 UTR 6 base pair
deletion (1494del) were associated with tumor RR or other measures
of outcome in any of the three treatment arms (data not shown).
DISCUSSION
All biomarkers must be considered in the context of biologic plausi-
bility as we strive to clarify their associations with clinical outcome. In
this study, the impact of pharmacogenetic predictors of adverse events
or efficacy was largely dependent on the specific therapeutic regimen
being used. This should be no surprise, in that factors such as drug
dose and concomitant therapy will have an important influence on the
predictive power of any genetic variant relevant to drug transport,
activation, or metabolism. This was illustrated by our findings relating
the UGT1A1*28 variant and neutropenia. The risk of severe neutro-
penia was not dramatically influenced by UGT1A1 genotype in the
IFL arm, where the dose of IRN in most patients was 100 mg/m2
weekly for 4 of 6 weeks. However, a clinically significant interaction
with UGT1A1*28 was evident in patients receiving IROX for both
neutropenia and vomiting. The administration of IRN in the IROX
regimen at twice the dose of the IFL regimen, and with a concomitant
marrow toxin (oxaliplatin), was associated with an unacceptable inci-
dence of adverse events in the homozygous UGT1A1*28 patients.19
This matrix effect is particularly important in light of the US
Food and Drug Administration changes to the IRN package insert,
where UGT1A1*28 genotype is included in the risk variables. The
N9741 data suggest that the IRN package insert requires greater pre-
cision about the factors that would make UGT1A1*28 genotype anal-
ysis required for patient management.19 The need for greater clinical
nuance is a theme that is also seen for the genetic prediction of warfa-
rin dose, which is greatly strengthened when applied in the context of
demographic and clinical factors, such as patient body size and inter-
acting medications.20,21 There is a strong need to define a clear path-
way for translating genetics into clinical guidance, or we will be buried
under an enormous number of potentially useful markers.
Detoxification by glutathione has been shown to influence plat-
inum DNA adduct levels in preclinical models and response in small
clinical cohorts. Our data demonstrated no clear relationship between
genetic variants in either GSTP1 or GSTM1 and tumor response.
However, the GSTP1 T/T genotype appears to influence toxicity risk
in the oxaliplatin-containing regimens. The GSTP1 T/T genotype was
associated with a heightened risk of both neutropenia and need to
discontinue therapy due to neurotoxicity in patients on FOLFOX
therapy. Patients with the GSTP1 T/T genotype on IROX also had a
higher incidence of neurotoxicity. Because oxaliplatin-associated neu-
rotoxicity is a major reason for discontinuing active chemotherapy for
CRC, tools that prospectively identify patients at high risk for toxicity,
if validated, would be clinically useful.
In our analysis, CYP3A5 genetic variants appear to identify pa-
tient groups with differential likelihood of tumor response from IFL
treatment. Co-administration of drugs or herbs that inhibit CYP3A
enzymes alter IRN pharmacokinetics and are associated with toxicity.
However, to the best of our knowledge, this is the first study to evaluate
the impact of CYP3A5 genetic variants in a large patient cohort. The
association with CYP3A5 and response to IFL, but not FOLFOX or
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Fig 4. Relationship between CYP3A5*3C genotype and confirmed response.
IFL, fluorouracil (FU)  irinotecan (IRN); FOLFOX, FU  oxaliplatin; IROX,
IRN  oxaliplatin.
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differences in RR (29% v 60%), if validated, would provide valuable
information for clinical discussions with patients but not to the point
of denying patients access to IRN therapy.
An important outcome of this study is that it clearly establishes
that pharmacogenetic studies can be successfully conducted in large,
multicenter, international research studies. The study was successfully
performed at small community practice sites, as well as larger commu-
nity clinical oncology programs and comprehensive cancer centers.
Indeed, most large clinical trials in the National Cancer Institute
cooperative group system now include sampling of peripheral blood
for pharmacogenetics.22 The data from this study are an initial assess-
ment of the utility and potential for large collections of germline DNA
to enhance our understanding of disease and patient management.
This study assessed genetic variation only in the germline DNA
from blood. While this approach has utility for both toxicity and
efficacy end points, there will be important sources of genetic variation
in drug effect that are missed. Specifically, somatic mutations in tumor
tissue (or cancer cells shed into blood or stool) were not assessed
because of the lack of availability of tumor tissue for most patients
enrolled. The recently detailed impact of KRAS mutations on the
activity of epidermal growth factor receptor antagonists clearly dem-
onstrates the importance of including tissue banking as part of large
clinical trials to provide an avenue to both discovery and validation of
clinically important markers.23
This study focused on gene variants from published associations
with adverse events or antitumor activity.5-7 Most of these previous
reports were small ( 100 patients), single-institution studies, with no
randomized comparisons to give context to the results. Not surpris-
ingly, most of the previous findings were not replicated in this study.
In some cases, the explanation is likely to be one of logistics, such as the
differences in IRN dosing7 or FU schedule.24,25 However, many of the
previous findings may be false positives, possibly because of issues of
multiple comparisons, nonrepresentative patient samples, the fact
that multicenter studies such as N9741 also incorporate the subtle
variations in patient management that are masked when only a
limited number of centers are included, or the absence of a valida-
tion cohort.26 These include ABCB1 3435 CT, CYP3A4*1B, and
MTHFR 677 CT.
As we consider the critical need to discover and validate predic-
tive markers, there will also be additional genes of pharmacologic
importance that emerge from current scientific investigations, includ-
ing drug transporters. Putative predictive markers must not be con-
sidered in isolation, but rather the analysis must include other
important factors, including pathologic findings and patient demo-
graphics. The use of robust data sets will allow greater clarity in our
quest for predictors of patient therapy.
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